Addendum...Of Interest this Week

Addendum...Of Interest this Week.

Addendum...Of Interest this Week

Botox Shots Approved for Migraines, article in the Wall Street Journal. On Friday, the FDA approved Botox from Allergan as a treatment to prevent migraines, a little more than a month after the company agreed to pay $600 million to settle allegations that it had illegally marketed the drug for unapproved uses like headaches for years. Another article on this topic was published in the New York Times on October 15th.

When Drugs like Avandia Cause Problems they are suppose to Prevent, Oct.16th New York Times. In the past weeks, the FDA has noticed that two types of drugs that were suppose to prevent serious medical problems were, in fact, causing them.

The Court’s Pre-emption Test, article published on October 18th in the New York Times. Where state efforts to protect citizens and compensate victims don’t conflict with federal law, pre-emption should not be used as a weapon.

Breast Cancer seen as Riskier with Hormone, October 19th Wall street Journal and New York Times articles. Research found that hormone therapy for breast cancer speeds up the growth of the tumor.

Judge signals she’ll let Ruling on Military Policy stand, October 19th in the New York Times. Do we give the military the power to have absurd rules for fear of preventing a slippery slope or is there a way to have the military follow the constitution and still operate?
 

Payments to Doctors by most Pharma Companies still remains secret, published in Pro Publica on Oct. 20th. Consumers hoping to know more about the Doctor payments by Pharmaceutical companies will have to wait until 2013 for such disclosures to be made industry-wide.

Wall Street Journal article, MySpace apps leak user data, October 23rd. A Wall Street Journal investigation found that MySpace and popular applications of the networking site have been transmitting data to outside advertising companies that could be used to identify users.

For-profit Colleges Oppose Tighter Regulations. Part of a government plan to more closely regulate the for-profit education sector in the United States has been delayed, following an outcry from school supporters. Article in the New York Times, Oct.24th.
 

Shawn Khorrami Quoted in Daily Journal Article Focusing on Avandia

Shawn Khorrami was quoted in today's issue of the Daily Journal article "Doctors Split on Pulling Diabetes Drug."

The article provides a recap of the recent decision by an FDA advisory panel to not pull the type II diabetes medication off of the market, despite warnings from doctors and scientists.  "We've heard there's at least some agreement between scientists out there that it shouldn't be on the market," Shawn said. 

Shawn and KPA are responsible for approximately 600 individuals who were harmed by Avandia.  Discovery in these cases is currently ongoing and Shawn is hopeful of these cases being resolved shortly.

 

 

FDA Gets One Step Closer to Protecting Consumers

According to an article in today's LA Times, next week the FDA has scheduled a two-day meeting to determine the future of the popular diabetes pill, Avandia. 

The GlaxoSmithKline pharmaceutical, which is still on the market, has been linked to dangerous side-effects such as heart attack and death.  Consumers who have been affected by the drug are getting closer to receiving compensation for their damages, but the fight is still far from over.

This highly controversial pharmaceutical treats type II diabetes, which affects nearly 20 million Americans.  Studies by such organizations as the Journal of the American Medical Association are reporting on dangers of increased chances of cardiovascular threats from using Avandia over other diabetes drugs. 

 

 

Diabetes Drug Avandia Still Causing Debate

Coverage on the popular GlaxoSmithKline medicine, Avandia, has recently sparked due to a new Senate report.  Although hundreds of individuals suffer each month from the dangerous side affects associated with the drug, the drug still remains on the market.  A better look at these latest developments can be read in this NY Times article - "Research Ties Diabetes Drug to Heart Woes"

Shawn Khorrami and James Kenna of KPA have been appointed to the JCCP Steering Committee for Avandia, and will continue to fight on behalf of those injured individuals.